share_log

Theriva Biologics | 8-K: Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics | 8-K: Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics | 8-K：Theriva™ Biologics公布2024年第二季度运营亮点和财务业绩
美股SEC公告 ·  2024/08/13 20:07

Moomoo AI 已提取核心信息

Theriva Biologics reported Q2 2024 financial results with $16.6 million cash position expected to provide runway into Q2 2025. The company's Phase 2b VIRAGE trial of VCN-01 in metastatic pancreatic cancer is nearing completion of enrollment in Q3 2024. The FDA granted Fast Track Designation for VCN-01 in pancreatic cancer and Rare Pediatric Disease Designation for retinoblastoma treatment.Q2 financial results showed decreased operating expenses, with G&A expenses down 45% to $1.5 million and R&D expenses slightly lower at $3.0 million compared to Q3 2023. The company recorded a $4.0 million goodwill impairment charge, while maintaining $19.2 million in IPR&D assets. Other income was $172,000, primarily from interest earnings.The company continues to advance its lead candidate VCN-01, an oncolytic virus designed for co-administration with chemotherapy. The VIRAGE trial is evaluating VCN-01 combined with gemcitabine/nab-paclitaxel as first-line therapy in metastatic pancreatic cancer patients, aiming to enroll 92 evaluable patients across U.S. and Spain sites.
Theriva Biologics reported Q2 2024 financial results with $16.6 million cash position expected to provide runway into Q2 2025. The company's Phase 2b VIRAGE trial of VCN-01 in metastatic pancreatic cancer is nearing completion of enrollment in Q3 2024. The FDA granted Fast Track Designation for VCN-01 in pancreatic cancer and Rare Pediatric Disease Designation for retinoblastoma treatment.Q2 financial results showed decreased operating expenses, with G&A expenses down 45% to $1.5 million and R&D expenses slightly lower at $3.0 million compared to Q3 2023. The company recorded a $4.0 million goodwill impairment charge, while maintaining $19.2 million in IPR&D assets. Other income was $172,000, primarily from interest earnings.The company continues to advance its lead candidate VCN-01, an oncolytic virus designed for co-administration with chemotherapy. The VIRAGE trial is evaluating VCN-01 combined with gemcitabine/nab-paclitaxel as first-line therapy in metastatic pancreatic cancer patients, aiming to enroll 92 evaluable patients across U.S. and Spain sites.
Theriva生物制品发布了2024年第二季度财务业绩，现金储备为1660万，预计能够支撑到2025年第二季度。该公司的20亿VIRAGE试验正在进行中的VCN-01针对转移性胰腺癌的患者招募，预计在2024年第三季度完成招募。FDA已授予VCN-01在胰腺癌治疗中的快速通道认证和在视网膜母细胞瘤治疗中的罕见儿科疾病认证。第二季度财务结果显示营业费用有所减少，其中一般和行政费用下降45%，降至150万，研发费用也略微下降至300万，相较于2023年第三季度。公司计入400万的商誉减值损失，同时保持1920万的知识产权与开发资产。其他收入为172,000，主要来源于利息收入。公司继续推进其主要候选药物VCN-01，这是一种旨在与化疗联合使用的溶瘤病毒。VIRAGE试验评估VCN-01与吉西他滨/纳布紫杉醇联合用作转移性胰腺癌患者的一线疗法，目标是在美国和西班牙地区招募92名可评估患者。
Theriva生物制品发布了2024年第二季度财务业绩，现金储备为1660万，预计能够支撑到2025年第二季度。该公司的20亿VIRAGE试验正在进行中的VCN-01针对转移性胰腺癌的患者招募，预计在2024年第三季度完成招募。FDA已授予VCN-01在胰腺癌治疗中的快速通道认证和在视网膜母细胞瘤治疗中的罕见儿科疾病认证。第二季度财务结果显示营业费用有所减少，其中一般和行政费用下降45%，降至150万，研发费用也略微下降至300万，相较于2023年第三季度。公司计入400万的商誉减值损失，同时保持1920万的知识产权与开发资产。其他收入为172,000，主要来源于利息收入。公司继续推进其主要候选药物VCN-01，这是一种旨在与化疗联合使用的溶瘤病毒。VIRAGE试验评估VCN-01与吉西他滨/纳布紫杉醇联合用作转移性胰腺癌患者的一线疗法，目标是在美国和西班牙地区招募92名可评估患者。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？